Wu Mengwan, Guo Jing, Guo Lihong, Zuo Qiang
Department of Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong Province, 510515, China.
Tumour Biol. 2016 Sep;37(9):12525-12533. doi: 10.1007/s13277-016-5122-y. Epub 2016 Jun 25.
Recent studies have demonstrated the prognostic value of the C-reactive protein/albumin (CRP/Alb) ratio in cancer. However, the role of the CRP/Alb ratio in advanced pancreatic cancer (PC) has not been examined. A retrospective study of 233 patients with advanced PC was conducted. We investigated the relationship between the CRP/Alb ratio, clinicopathological variables, and overall survival (OS). The optimal cutoff point of the CRP/Alb ratio was 0.54. A higher CRP/Alb ratio was significantly associated with an elevated neutrophil-lymphocyte ratio (NLR) (P < 0.001) and higher modified Glasgow prognostic score (mGPS) (P < 0.001). Using univariate analyses, we found that the age (P = 0.009), disease stage (P < 0.001), NLR (P < 0.001), mGPS (P < 0.001), and CRP/Alb ratio (P < 0.001) were significant predictors of OS. Patients with a higher CRP/Alb ratio had a worse OS than patients with a lower CRP/Alb ratio (hazard ratio (HR) 3.619; 95 % CI 2.681-4.886; P < 0.001). However, the CRP/Alb ratio was identified as the only inflammation-based parameter with an independent prognostic ability in the multivariate analyses (P < 0.001). The pretreatment CRP/Alb ratio is a superior prognostic and therapeutic predictor of OS in advanced PC.
近期研究已证实C反应蛋白/白蛋白（CRP/Alb）比值在癌症中的预后价值。然而，CRP/Alb比值在晚期胰腺癌（PC）中的作用尚未得到研究。对233例晚期PC患者进行了一项回顾性研究。我们调查了CRP/Alb比值、临床病理变量与总生存期（OS）之间的关系。CRP/Alb比值的最佳截断点为0.54。较高的CRP/Alb比值与中性粒细胞-淋巴细胞比值（NLR）升高（P<0.001）和改良格拉斯哥预后评分（mGPS）升高（P<0.001）显著相关。通过单因素分析，我们发现年龄（P=0.009）、疾病分期（P<0.001）、NLR（P<0.001）、mGPS（P<0.001）和CRP/Alb比值（P<0.001）是OS的显著预测因素。CRP/Alb比值较高的患者的OS比CRP/Alb比值较低的患者更差（风险比（HR）3.619；95%CI 2.681-4.886；P<0.001）。然而，在多因素分析中，CRP/Alb比值被确定为唯一具有独立预后能力的基于炎症的参数（P<0.001）。治疗前CRP/Alb比值是晚期PC患者OS的一个优越的预后和治疗预测指标。
